123 related articles for article (PubMed ID: 37938093)
1. Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
Ou J; Xu X; Deng S; Liang H; Cai Z; Li J; Huang Z; Tang B; Wang Z; Zhou Y; Liu X; Liu Q; Zhou H
Leuk Lymphoma; 2024 Feb; 65(2):219-227. PubMed ID: 37938093
[TBL] [Abstract][Full Text] [Related]
2. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
[TBL] [Abstract][Full Text] [Related]
4. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
5. The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort study.
Gupta S; Pole JD; Baxter NN; Sutradhar R; Lau C; Nagamuthu C; Nathan PC
Cancer Med; 2019 May; 8(5):2095-2103. PubMed ID: 30912628
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective Analysis of the Impact of Treatment on Prognosis in 44 Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia].
Chen XP; Lv N; Li YH; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):14-8. PubMed ID: 26913386
[TBL] [Abstract][Full Text] [Related]
7. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
[TBL] [Abstract][Full Text] [Related]
9. [Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].
Zheng YZ; Zheng H; Chen ZS; Hua XL; Le SH; Li J; Hu JD
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):19-25. PubMed ID: 35231988
[No Abstract] [Full Text] [Related]
10. TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
Yu CH; Chang WT; Jou ST; Lin TK; Chang YH; Lin CY; Lin KH; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Su YN; Hung CC; Lin DT; Chen HY; Yang YL
Cancer Sci; 2020 Jan; 111(1):229-238. PubMed ID: 31729120
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
12. [Treatment strategy for acute lymphoblastic leukemia in adolescent and young adults].
Yamazaki E
Rinsho Ketsueki; 2022; 63(7):826-832. PubMed ID: 35922954
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].
Du YY; Lyu KK; Xu MM; Yao WQ; Kang HZ; Han Y; Tang XW; Ma X; Wu XJ; He XF; Wu DP; Liu YJ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):396-401. PubMed ID: 34218582
[No Abstract] [Full Text] [Related]
14. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
[TBL] [Abstract][Full Text] [Related]
15. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Fasan A; Haferlach C
Leukemia; 2017 Mar; 31(3):705-711. PubMed ID: 27680515
[TBL] [Abstract][Full Text] [Related]
16. Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
Chen H; Qin Y; Yang J; Liu P; Zhang C; He X; Zhou S; Yang S; Gui L; Zhou L; Sun Y; Shi Y
Ann Hematol; 2020 Dec; 99(12):2847-2857. PubMed ID: 32712792
[TBL] [Abstract][Full Text] [Related]
17. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.
Yan B; Chen Q; Xu J; Li W; Xu B; Qiu Y
Leukemia; 2020 Jul; 34(7):1816-1827. PubMed ID: 31988438
[TBL] [Abstract][Full Text] [Related]
18. Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia - A multicenter prospective registry in Thai population.
Limvorapitak W; Owattanapanich W; Utchariyaprasit E; Niparuck P; Puavilai T; Tantiworawit A; Rattanathammethee T; Saengboon S; Sriswasdi C; Julamanee J; Saelue P; Polprasert C; Wudhikarn K; Wanitpongpun C; Prayongratana K;
Leuk Res; 2019 Dec; 87():106235. PubMed ID: 31675661
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
20. Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Int J Cancer; 2023 Mar; 152(5):977-985. PubMed ID: 36251447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
